ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OXP Oxford Pharm Gp

1.50
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Pharm Gp LSE:OXP London Ordinary Share GB00B3LXPB43 ORD 0.001P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.50 1.45 1.55 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Oxford Pharmascience Group PLC Subdivision of Capital (3192Y)

04/12/2017 2:14pm

UK Regulatory


Oxford Pharm Gp (LSE:OXP)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Oxford Pharm Gp Charts.

TIDMOXP

RNS Number : 3192Y

Oxford Pharmascience Group PLC

04 December 2017

Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")

Subdivision of Capital

Oxford Pharmascience Group plc (AIM: OXP) announces that, as contemplated in the Circular to Shareholders issued by the Company on 10 November 2017 and pursuant to the resolutions passed at a general meeting of shareholders on 27 November 2017, the Company has completed a subdivision of its capital whereby each Existing Share of GBP0.001 has been subdivided and reclassified into 1 New Share of GBP0.00001 and 1 Participating Deferred Share of GBP0.00099 (the "Subdivision").

Following the Subdivision the issued share capital of the Company consists of 1,205,661,619 New Shares of GBP0.00001 each and 1,205,661,619 Participating Deferred Shares of GBP0.00099 each.

Following the Subdivision, each Existing Shareholder's holding shall remain unchanged therefore no new share certificates will be issued. The total voting rights in the Company also remains unchanged, with 1,205,661,619 New Shares in issue. This figure may be used by Shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The Capital Reduction remains subject to the Court's approval and a further announcement in relation to this and the Demerger will be made in due course.

Unless otherwise indicated, capitalised terms in this announcement have the meaning given to them in the definitions appearing in the circular issued by the Company on 10 November 2017.

For further information please contact:

 
 Oxford Pharmascience Group 
  Plc 
-----------------------------  ----------------- 
 Chris Hill, Chief Financial 
  Officer                       +44 20 7554 5875 
-----------------------------  ----------------- 
 
 N+1 Singer (Nominated 
  Adviser & Broker) 
-----------------------------  ----------------- 
 Aubrey Powell/Jen Boorer       +44 20 7496 3000 
-----------------------------  ----------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCOKQDDQBDDDBK

(END) Dow Jones Newswires

December 04, 2017 09:14 ET (14:14 GMT)

1 Year Oxford Pharm Gp Chart

1 Year Oxford Pharm Gp Chart

1 Month Oxford Pharm Gp Chart

1 Month Oxford Pharm Gp Chart

Your Recent History

Delayed Upgrade Clock